Correspondence
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative

https://doi.org/10.1016/S2468-1253(20)30392-7Get rights and content

Cited by (0)

Joint senior authors

View Abstract